Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Heymach on Nivolumab for Lung Cancer

John V. Heymach, MD, PhD
Published: Friday, Apr 14, 2017



John V. Heymach, MD, PhD, chairman, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses efficacy findings with nivolumab (Opdivo) results for patients with metastatic lung cancer.

There is now 5 years of follow-up for patients treated with nivolumab, explains Heymach. This is one of the first studies that demonstrated a positive result from immunotherapy for patients with metastatic lung cancer.

This is a significant step forward in the field, states Heymach. Patients are now becoming long-term survivors, making immunotherapy a viable treatment option.
 


John V. Heymach, MD, PhD, chairman, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses efficacy findings with nivolumab (Opdivo) results for patients with metastatic lung cancer.

There is now 5 years of follow-up for patients treated with nivolumab, explains Heymach. This is one of the first studies that demonstrated a positive result from immunotherapy for patients with metastatic lung cancer.

This is a significant step forward in the field, states Heymach. Patients are now becoming long-term survivors, making immunotherapy a viable treatment option.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x